‘Local anaesthetic could help migraine sufferers’
There is currently no cure for migraines, although a number of treatments are available to help ease the symptoms.
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Patients with hard-to-treat migraines could get some relief from a local anaesthetic, a new study suggests.
There is currently no cure for migraines, though a range of treatments are offered to patients to help ease symptoms.
But, for some, their headache persists despite standard or aggressive treatments.
Researchers set out to examine the effectiveness of whether am infusion of lidocaine, a local anaesthetic, could help “break the cycle” of pain among patients admitted to hospital.
The treatment has been used for some patients but the evidence is “limited”, they said.
Intravenous infusions are indicated to rapidly ’break the cycle’ of pain. Lidocaine infusions may be effective but evidence is limited
The team, led by academics from the University of Philadelphia, examined data on 609 patients who received the treatment alongside other migraine treatments.
Participants were asked to rate their pain before their hospital admission and as they left on a scale of zero to 10.
When they were admitted the average pain score was seven.
But after the lidocaine infusion, along with the other treatments, patients reported that their pain rating was, on average, just one.
Participants were followed up one to two months after they were discharged and reported an average pain score of 5.5.
They also reported that they were experiencing fewer “headache days” – down from 27 days per month at the start of the study to 23 days at follow-up.
The authors called for a larger study to confirm the findings and assess how beneficial lidocaine infusions could be to help people with chronic migraines who have not responded to other treatments.
“Lidocaine infusions may be associated with short-term and medium-term pain relief in refractory chronic migraine,” they wrote in the journal Regional Anesthesia & Pain Medicine.
“This study provides a rational basis for performing a randomised controlled trial to evaluate lidocaine infusions as an effective treatment for refractory chronic migraine.”